Cash and cash equivalents

Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

Retrieved on: 
Thursday, February 27, 2020

In January of this year, partial responses in liver, melanoma, gastro-esophageal junction, and head and neck cancers were reported.

Key Points: 
  • In January of this year, partial responses in liver, melanoma, gastro-esophageal junction, and head and neck cancers were reported.
  • In 2019, Adaptimmune announced agreements with Alpine Immune Sciences and Noile-Immune to develop further next-generation products.
  • Adrian Rawcliffe assumed the role of Chief Executive Officer effective September 1, 2019 and John Lunger became Chief Patient Supply Officer effective August 1, 2019.
  • Financial Results for the fourth quarter and year ended December 31, 2019
    Cash / liquidity position: As of December 31, 2019, Adaptimmune had cash and cash equivalents of $50.4million and Total Liquidity1 of $89.5 million.

Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Retrieved on: 
Thursday, February 27, 2020

Fourth Quarter and Full Year 2019 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2019 Financial Results:
    Cash position: As of December31, 2019, cash, cash equivalents and investments were $170.4 million, compared to $195.9 million as of December31, 2018.
  • Research and development expenses: Research and development expenses were $16.6 million for both the fourth quarter of 2019 and 2018.
  • The increase in general and administrative expenses for both the fourth quarter of 2019 and the full year 2019 was primarily attributable to increased employee compensation costs.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Dassault Aviation : Financial Release - Full year 2019 Results

Retrieved on: 
Thursday, February 27, 2020

In 2020, the Group plans to deliver 40 Falcon (iso 2019) and 13 Rafale (vs. 26 in 2019) and lower net sales.

Key Points: 
  • In 2020, the Group plans to deliver 40 Falcon (iso 2019) and 13 Rafale (vs. 26 in 2019) and lower net sales.
  • 2019 adjusted net financial income was EUR -52 million compared to EUR -77 million in 2018.
  • It covers the following balance sheet items: cash and cash equivalents, current financial assets (at market value) and financial debts.
  • Borrowings and financial debt amounted to EUR 558 million as of December 31, 2019, compared to EUR 991 million as of December 31, 2018.

Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial Results

Retrieved on: 
Wednesday, February 26, 2020

ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (Zomedica or Company), a veterinary diagnostic company, announced consolidated financial results for the year ended December 31, 2019.

Key Points: 
  • ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (Zomedica or Company), a veterinary diagnostic company, announced consolidated financial results for the year ended December 31, 2019.
  • Zomedica, which is in the development stage, recorded no revenues in 2019.
  • Zomedica had cash and cash equivalents of $510,586 as of December 31, 2019, compared to $1,940,265 as of December 31, 2018.
  • As of December 31, 2019, and December 31, 2018, Zomedica had shareholders equity of $2,059,459 and $3,657,000, respectively.

Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

Retrieved on: 
Wednesday, February 26, 2020

SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December31, 2019 and provided an update on the companys recent achievements.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December31, 2019 and provided an update on the companys recent achievements.
  • Cash and cash equivalents totaled $191.2 million at December 31, 2019 compared with $157.1 million at December 31, 2018.
  • Research and development expenses for the fourth quarter of 2019 were$13.9 million, as compared to$8.3 millionfor the same period in the prior year.
  • General and administrative expenses for the fourth quarter of 2019 were$5.5 million, as compared to$2.4 millionfor the same period in the prior year.

Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

Retrieved on: 
Wednesday, February 26, 2020

CONSHOHOCKEN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights:

Key Points: 
  • CONSHOHOCKEN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights:
    Madrigal made significant progress during 2019 in executing our business strategy and advancing the development of resmetirom.
  • Becky Taub, M.D., CMO and President, Research & Development of Madrigal added, According to plan, we initiated our Phase 3 MAESTRO-NASH clinical study in the first quarter, and our Phase 3 MAESTRO-NAFLD-1 study in the fourth quarter.
  • We were also pleased with the publication of our successful Phase 2 NASH study in The Lancet in 2019.
  • Financial Results for the Three Months and Twelve Months EndedDecember 31, 2019
    As of December 31, 2019, Madrigal had cash, cash equivalents and marketable securities of $439.0 million, compared to $483.7 million at December 31, 2018.

MicroVision Announces Preliminary Fourth Quarter 2019 Results

Retrieved on: 
Tuesday, February 25, 2020

REDMOND, Wash., Feb. 25, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc.( NASDAQ:MVIS ), a leader in innovative ultra-miniature projection display and sensing technology, today MicroVision announced preliminary fourth quarter 2019 results and the appointment of Sumit Sharma as Chief Executive Officer.

Key Points: 
  • REDMOND, Wash., Feb. 25, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc.( NASDAQ:MVIS ), a leader in innovative ultra-miniature projection display and sensing technology, today MicroVision announced preliminary fourth quarter 2019 results and the appointment of Sumit Sharma as Chief Executive Officer.
  • MicroVision announced selected financial information about its fourth quarter of 2019.
  • Fourth quarter 2019 operating expenses were approximately $4.5 million, and the net loss in the quarter was approximately $3.3 million.
  • Fourth quarter cash used in operations was approximately $4.3 million, and the company had $5.8 million in cash and cash equivalents at December 31, 2019.

Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

Retrieved on: 
Monday, February 24, 2020

In the fourth quarter of 2019, the IND for AMG 509 was allowed by the FDA, and Xencor received a $5 million milestone payment.

Key Points: 
  • In the fourth quarter of 2019, the IND for AMG 509 was allowed by the FDA, and Xencor received a $5 million milestone payment.
  • Fourth Quarter and Full Year Ended December 31, 2019 Financial Results
    Cash, cash equivalents and marketable securities totaled $601.3 million as of December 31, 2019, compared to $530.5 million on December 31, 2018.
  • Revenues for the fourth quarter ended December 31, 2019 were $3.5 million, compared to $11.6 million for the same period in 2018.
  • ET (1:30 p.m. PT) to discuss these fourth quarter and full year 2019 financial results and provide a corporate update.

ORYZON Reports Financial Results and Corporate Update for 4th Quarter and Year Ended December 31, 2019

Retrieved on: 
Monday, February 24, 2020

"Oryzon continued to make strong clinical progress in the fourth quarter, said Dr. Carlos Buesa, Oryzons Chief Executive Officer.

Key Points: 
  • "Oryzon continued to make strong clinical progress in the fourth quarter, said Dr. Carlos Buesa, Oryzons Chief Executive Officer.
  • Two of the 5 patients (40%) that had received more than 3 cycles of treatment had also become transfusion independent.
  • The company plans to report the results of this study at the AAT-AD/PD conference in April 2020 in Vienna, Austria.
  • Cash, cash equivalents and marketable securities totaled $39.6 million as of December 31, 2019, compared to $39.5 million as of December 31, 2018.

Tellurian Reports 2019 Results

Retrieved on: 
Monday, February 24, 2020

Tellurian Inc. (Tellurian) (NASDAQ: TELL) continued to build its integrated global natural gas business and concluded 2019 with momentum on commercialization and development of its first project, Driftwood LNG.

Key Points: 
  • Tellurian Inc. (Tellurian) (NASDAQ: TELL) continued to build its integrated global natural gas business and concluded 2019 with momentum on commercialization and development of its first project, Driftwood LNG.
  • Total also agreed to purchase approximately $200 million of Tellurian common stock, bringing its aggregate investment in the Tellurian portfolio to approximately $907 million upon a final investment decision for Driftwood.
  • Tellurian ended its 2019 fiscal year with approximately $64.6 million of cash and cash equivalents and approximately $136.6 million in debt.
  • Tellurian reported a net loss of approximately $151.8 million, or $0.69 per share (basic and diluted), for the year ended December 31, 2019.